Algiax Pharmaceuticals is a clinical-stage biotechnology company focused on developing GABAA receptor modulators to treat neuropathic pain and other indications with high unmet need. Its lead candidate, AP-325, is a small-molecule GABAA receptor modulator in clinical development for neuropathic pain. The company has advanced AP-325 into a planned proof-of-concept Phase IIa study called “CURE,” has filed a clinical trial application in the EU, and planned to start patient recruitment at the beginning of 2020. OCCIDENT commented that AP-325 and related compounds do not cross the blood-brain barrier, which could reduce central side effects and addiction potential compared with conventional approaches. Founded in 2011 and based in Düsseldorf, Germany, Algiax is also advancing a selection of Thioacrylamide (ThAc) derivatives from discovery toward preclinical characterization. Financially, the company recently raised €5.5 million to support its development and clinical programs. Algiax Pharmaceuticals GmbH is a biotechnology research company dedicated to drug development addressing central nervous system (CNS) illnesses and dysfunctions, with a focus on neuropathic pain. Founded in July 2011 and based in Erkrath, Germany, it is led by Managing Director Dr. Jürgen Schumacher. The company holds patented substances currently in late preclinical development that target the symptoms of neuropathic pain and aim to enable causal therapy of pain induction. Algiax has raised €4.3m in funding to advance its program. Backers include High‑Tech Gründerfonds, private investors and KfW. The company intends to use the funds to gain approval for the clinical testing stage.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2019